Actinium Pharmaceuticals
ATNM
26 hedge funds and large institutions have $5.14M invested in Actinium Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
1,286% more call options, than puts
Call options by funds: $97K | Put options by funds: $7K
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0.02% more ownership
Funds ownership: 0.22% → 0.24% (+0.02%)
4% less funds holding
Funds holding: 27 → 26 (-1)
9% less capital invested
Capital invested by funds: $5.65M → $5.14M (-$510K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$559K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$207K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$114K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$55.7K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$21.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$136K |
| 2 |
Renaissance Technologies
New York
|
-$114K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$23K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$20K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIM
26
Macroview Investment Management
Bethesda,
Maryland
| $1K | +$711 | +17 | New |
|
|
RJA
27
Raymond James & Associates
St Petersburg,
Florida
| – | -$23K | -511 | Closed |
|
|
28
UBS Group
Zurich,
Switzerland
| – | -$20K | -435 | Closed |
|
|
TSS
29
Two Sigma Securities
New York
| – | -$20K | -433 | Closed |
|
|
CLOS
30
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$8K | -167 | Closed |
|
ATNM Hedge Fund Activity: Q2 2017 in Review
26 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2017, worth a combined $5.14M — down 9% from $5.65M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ATNM and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Virtu KCG Holdings, adding an estimated $559K. The largest seller was BlackRock, cutting an estimated $136K.
- 26 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2017, down from 27 in Q1 2017.
- Funds reported $5.14M of Actinium Pharmaceuticals stock for Q2 2017, down 9% quarter-over-quarter.
- 3 funds opened new Actinium Pharmaceuticals positions in Q2 2017 and 4 closed out, a net change of -1 holder.
- The largest Actinium Pharmaceuticals buyer in Q2 2017 was Virtu KCG Holdings, an estimated $559K added.
- The largest Actinium Pharmaceuticals seller in Q2 2017 was BlackRock, an estimated $136K sold.
Based on aggregated 13F filings for Q2 2017.